# A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma

> **NCT03096912** · PHASE2 · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Liposarcomas, Dedifferentiated
- Liposarcoma - Well Differentiated
- Liposarcoma; Mixed Type
- Soft-Tissue Sarcoma

## Interventions

- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT03096912
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2019-12
- **Final completion:** 2020-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03096912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03096912, "A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03096912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*